Novartis' Neulasta knockoff moves ahead at FDA; Vertex nabs two new Kalydeco approvals in EU;

> Novartis' ($NVS) Sandoz unit closed in on another Amgen ($AMGN) blockbuster with its FDA filing for approval of a biosimilar Neulasta; the Swiss drugmaker launched its Neupogen knockoff Zarxio earlier this year. Release | Report

> Vertex Pharmaceuticals ($VRTX) won two new approvals in Europe for Kalydeco, its cystic fibrosis treatment and blockbuster hopeful. Release

> Isis Pharmaceuticals ($ISIS), a California biotech, is considering changing its name in the wake of the terrorist attacks in Paris. Report

> Sales of a Viagra knockoff in China are swelling, with one company reporting $109 million in revenue for the drug in its first year. Report

> Merck KGaA and Pfizer ($PFE) won FDA breakthrough status for their cancer fighter avelumab, a PD-L1 immunotherapy. Report

And Finally ... Coffee drinkers may be less likely to die from a variety of diseases, including diabetes. Report

Suggested Articles

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.

Sanofi and Regeneron's blockbuster Dupixent is eyeing an approval in eosinophilic esophagitis after cutting patients' difficulty breathing.